LenioBio Earns Prestigious EU STEP Seal: A Signal of Excellence for Investors

The STEP Seal is a new initiative from the European Commission, designed to spotlight projects and technologies with clear strategic value for Europe and support further investments. This recognition reinforces LenioBio's leadership in transforming biomanufacturing. It demonstrates that the company's technology has met stringent evaluation standards, marking it as a compelling and timely investment opportunity in the strategic healthcare arena.

"We are honoured to receive the STEP Seal, as it affirms our commitment to pioneering advancements in biomanufacturing," said André Goerke, CEO at LenioBio. "The STEP validates the transformative potential of our technology and serves as a strong signal to investors that our platform is in line with the European Union's strategic priorities in healthcare."

LenioBio's project (Project Number: EU4H-2024-PJ-01-3) represents a significant step toward transforming the production of critical protein medicines. With its focus on enhancing cost efficiency and scalability, the project is set to play a vital role in meeting current and future healthcare needs across Europe.

About LenioBio GmbH 

LenioBio GmbH is a life sciences biotech company dedicated to transforming protein production through its proprietary ALiCE® technology. By eliminating the limitations and bottlenecks of traditional cell-based systems, LenioBio empowers researchers to explore new frontiers in protein expression and accelerate the development of cutting-edge therapeutics and diagnostics. 

View original content:https://www.prnewswire.co.uk/news-releases/leniobio-earns-prestigious-eu-step-seal-a-signal-of-excellence-for-investors-302400036.html